Real-space navigation testing differentiates between amyloid-positive and -negative aMCI

Neurology. 2020 Feb 25;94(8):e861-e873. doi: 10.1212/WNL.0000000000008758. Epub 2020 Jan 2.

Abstract

Objective: To distinguish between patients with amyloid-positive (A+) and -negative (A-) amnestic mild cognitive impairment (aMCI) by simultaneously investigating navigation performance, visual exploration behavior, and brain activations during a real-space navigation paradigm.

Methods: Twenty-one patients with aMCI were grouped into A+ (n = 11) and A- cases by amyloid-PET imaging and amyloid CSF levels and compared to 15 healthy controls. Neuropsychological deficits were quantified by use of the Consortium to Establish a Registry for Alzheimer's Disease-plus cognitive battery. All participants performed a navigation task in which they had to find items in a realistic spatial environment and had to apply egocentric and allocentric route planning strategies. 18F-fluorodeoxyglucose was injected at the start to detect navigation-induced brain activations. Subjects wore a gaze-controlled, head-fixed camera that recorded their visual exploration behavior.

Results: A+ patients performed worse during egocentric and allocentric navigation compared to A- patients and controls (p < 0.001). Both aMCI subgroups used fewer shortcuts, moved more slowly, and stayed longer at crossings. Word-list learning, figural learning, and Trail-Making tests did not differ in the A+ and A- subgroups. A+ patients showed a reduced activation of the right hippocampus, retrosplenial, and parietal cortex during navigation compared to A- patients (p < 0.005).

Conclusions: A+ patients with aMCI perform worse than A- patients with aMCI in egocentric and allocentric route planning because of a more widespread impairment of their cerebral navigation network. Navigation testing in real space is a promising approach to identify patients with aMCI with underlying Alzheimer pathology.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Amnesia / cerebrospinal fluid
  • Amnesia / complications
  • Amnesia / physiopathology*
  • Amyloid / cerebrospinal fluid*
  • Case-Control Studies
  • Cerebral Cortex / physiopathology
  • Cognitive Dysfunction / cerebrospinal fluid
  • Cognitive Dysfunction / complications
  • Cognitive Dysfunction / physiopathology*
  • Female
  • Fluorodeoxyglucose F18 / metabolism
  • Functional Neuroimaging
  • Hippocampus / physiopathology
  • Humans
  • Male
  • Middle Aged
  • Neuropsychological Tests
  • Positron-Emission Tomography
  • Spatial Navigation / physiology*
  • Visual Perception / physiology*

Substances

  • Amyloid
  • Fluorodeoxyglucose F18